The ongoing global COVID-19 pandemic has thrown into sharp relief the gap between modern biology’s ability to investigate and respond to a novel pathogen and modern medicine’s ability to marshal effective front-line interventions to limit its immediate health impact. While we have witnessed the rapid development of innovative vaccines against SARS-CoV-2 using novel molecular platforms, these have yet to alter the pandemic’s long-term trajectory in all but a handful of high-income countries. Health workers at the clinical front lines have little more in their clinical armamentarium than was available a century ago—chiefly oxygen and steroids—and yet advances in modern immunology and immunotherapeutics suggest an underuse of extant and effective, if unorthodox, therapies, which we now call “Extreme Immunotherapies for Pandemics (EIPs).”
CITATION STYLE
Nixon, D. F., Marín-Hernández, D., & Hupert, N. (2021). Extreme immunotherapy: emergency immunology to defeat pandemics. Molecular Medicine, 27(1). https://doi.org/10.1186/s10020-021-00366-4
Mendeley helps you to discover research relevant for your work.